GR MD 02

Drug Profile

GR MD 02

Alternative Names: Galactoarabino-rhamnogalaturonate

Latest Information Update: 19 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Galectin Therapeutics
  • Developer Galectin Therapeutics; Providence Cancer Center; Providence Health & Services
  • Class Antifibrotics; Antineoplastics; Antipsoriatics; Carbohydrates; Hepatoprotectants; Polysaccharides; Skin disorder therapies
  • Mechanism of Action Galectin 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Hepatic fibrosis; Liver cirrhosis; Plaque psoriasis
  • Phase I Head and neck cancer; Lung cancer; Malignant melanoma; Orofacial cancer
  • Preclinical Breast cancer; Diabetic nephropathies; Fibrosis; Prostate cancer; Pulmonary fibrosis; Renal fibrosis
  • Discontinued Non-alcoholic steatohepatitis

Most Recent Events

  • 14 Dec 2017 GR MD 02 is available for licensing as of 14 Dec 2017. http://galectintherapeutics.com/
  • 14 Dec 2017 Efficacy data from the phase IIb NASH-CX trial in Non-alcoholic steatohepatitis released by Galectin Therapeutics
  • 05 Dec 2017 Efficacy data from a phase II trial in Non-alcoholic steatohepatitis released by Galectin Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top